• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Chiasma, Inc.

    6/24/21 4:29:36 PM ET
    $CHMA
    Major Pharmaceuticals
    Health Care
    Get the next $CHMA alert in real time by email
    SC 13G 1 rocksprings-chma06142021.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*



    Chiasma, Inc.

    (Name of Issuer)

     

    Common Stock, $0.01 par value

    (Title of Class of Securities)

     

    16706W102

    (CUSIP Number)

     

     

    June 14, 2021
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)

    x Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  16706W102
     SCHEDULE 13G
    Page 2 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Rock Springs Capital Management LP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    3,243,600
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    3,243,600
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    3,243,600
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    5.60%
    12
    TYPE OF REPORTING PERSON
     
    IA

     

     


     

    CUSIP No.  16706W102
     SCHEDULE 13G
    Page 3 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Rock Springs Capital LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    3,243,600
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    3,243,600
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    3,243,600
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    5.60%
    12
    TYPE OF REPORTING PERSON
     
    OO; HC

     

     


     

    CUSIP No.  16706W102
     SCHEDULE 13G
    Page 4 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Rock Springs Capital Master Fund LP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    3,086,039
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    3,086,039
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    3,086,039
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    5.33%
    12
    TYPE OF REPORTING PERSON
     
    PN

     

     
     

     

    CUSIP No.  16706W102
     SCHEDULE 13G
    Page 5 of 9 Pages

     

    Item 1.(a) Name of Issuer

    Chiasma, Inc. (the “Issuer”)

    (b) Address of Issuer’s Principal Executive Offices

    140 Kendrick Street, Building C East

    Needham, Massachusetts 02494

    Item 2.(a) Name of Person Filing

    This Statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”):

     

    i. Rock Springs Capital Management LP (“RSCM”);

    ii. Rock Springs Capital LLC (“RSC”); and

    iii. Rock Springs Capital Master Fund LP (“Master Fund”).

    This Statement relates to Shares (as defined herein) held directly by the Master Fund, which is a Cayman Island exempted limited partnership, and Four Pines Master Fund LP (“Four Pines”), which is a Cayman Islands exempted limited partnership, and indirectly held by RSCM, a Delaware limited partnership, and RSC, a Delaware limited liability company. RSCM serves as the investment manager to each of the Master Fund and Four Pines. RSC is the general partner of RSCM.

    (b) Address of Principal Business Office, or, if none, Residence

    Rock Springs Capital Management LP and Rock Springs Capital LLC

    650 South Exeter, Suite 1070

    Baltimore, MD 21202

     

    Rock Springs Capital Master Fund LP

    c/o Walkers Corporate Limited

    Cayman Corporate Centre

    27 Hospital Road

    George Town, Grand Cayman, KY1-9008, Cayman Islands

     

    (c) Citizenship

    Rock Springs Capital Management LP - Delaware

    Rock Springs Capital LLC - Delaware

    Rock Springs Capital Master Fund LP - Cayman Islands

     (d) Title of Class of Securities

    Common Stock, $0.01 par value (the “Shares”)

     (e) CUSIP No.:

    16706W102

     
     

     

    CUSIP No.  16706W102
     SCHEDULE 13G
    Page 6 of 9 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not Applicable.

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

     
     

     

    CUSIP No. 16706W102
     SCHEDULE 13G
    Page 7 of 9 Pages

     

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    As of the date of this filing, the Reporting Persons may be deemed to be the beneficial owners of 3,243,600 Shares, which amount includes 3,086,039 Shares directly beneficially owned by the Master Fund, and 157,561 Shares directly beneficially owned by Four Pines. The percent of class is determined by dividing the number of Shares beneficially owned by the Reporting Persons by 57,904,418 as reported on the Issuer’s Form 8-K filed on May 5, 2021.

    (a) Amount beneficially owned:

    Rock Springs Capital Management LP: 3,243,600

    Rock Springs Capital LLC: 3,243,600

    Rock Springs Capital Master Fund LP: 3,086,039

     

    (b) Percent of class:

    Rock Springs Capital Management LP: 5.60%

    Rock Springs Capital LLC: 5.60%

    Rock Springs Capital Master Fund LP: 5.33%

     

    (c) Number of shares as to which the person has:

     

    (i) Sole power to vote or to direct the vote:

    Rock Springs Capital Management LP: 0

    Rock Springs Capital LLC: 0

    Rock Springs Capital Master Fund LP: 0

     

    (ii) Shared power to vote or to direct the vote:

    Rock Springs Capital Management LP: 3,243,600

    Rock Springs Capital LLC: 3,243,600

    Rock Springs Capital Master Fund LP: 3,086,039

     

    (iii) Sole power to dispose or to direct the disposition of:

    Rock Springs Capital Management LP: 0

    Rock Springs Capital LLC: 0

    Rock Springs Capital Master Fund LP: 0

     

    (iv) Shared power to dispose or to direct the disposition of:

    Rock Springs Capital Management LP: 3,243,600

    Rock Springs Capital LLC: 3,243,600

    Rock Springs Capital Master Fund LP: 3,086,039

    Item 5. Ownership of Five Percent or Less of a Class

     

    Not applicable.

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

     

    See disclosure in Items 2 and 4 hereof. Certain funds listed in Item 2(a) are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares covered by this Statement that may be deemed to be beneficially owned by the Reporting Persons.

     

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Please see response to Item 2.

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable.

    Item 9. Notice of Dissolution of Group

     

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     
     
    CUSIP No.  16706W102
     SCHEDULE 13G
    Page 8 of 9 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: June 24, 2021

     

     

     

    Rock Springs Capital Management LP

    By: Rock Springs Capital LLC, General Partner 

           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title: Member

     

      Rock Springs Capital LLC
           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title: Member

     

      Rock Springs Capital Master Fund LP
     

    By: Rock Springs Capital Management LP, Investment Manager

    By: Rock Springs Capital LLC, General Partner 

           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title: Member

     

     

     
     
    CUSIP No. 16706W102
     SCHEDULE 13G
    Page 9 of 9 Pages

     

     

    JOINT FILING AGREEMENT

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Date: June 24, 2021

     

     

     

    Rock Springs Capital Management LP

    By: Rock Springs Capital LLC, General Partner 

           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title:  Member

     

      Rock Springs Capital LLC
           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title:  Member

     

      Rock Springs Capital Master Fund LP
     

    By: Rock Springs Capital Management LP, Investment Manager

    By: Rock Springs Capital LLC, General Partner 

           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title:  Member

     

     

     

     

     

     

     

    Get the next $CHMA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CHMA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CHMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Chiasma, Inc. (Amendment)

      SC 13G/A - CHIASMA, INC (0001339469) (Subject)

      8/9/21 4:06:23 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed by Chiasma, Inc.

      SC 13G - CHIASMA, INC (0001339469) (Subject)

      6/24/21 4:29:36 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed by Chiasma, Inc.

      SC 13G - CHIASMA, INC (0001339469) (Subject)

      6/7/21 4:29:23 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care

    $CHMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: STONEPINE CAPITAL, L.P. returned 6,770,000 units of Common Stock to the company

      4 - CHIASMA, INC (0001339469) (Issuer)

      8/9/21 5:01:36 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: LUDLAM WILLIAM returned 11,799 units of Common Stock to the company, closing all direct ownership in the company

      4 - CHIASMA, INC (0001339469) (Issuer)

      8/5/21 6:05:08 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Mamluk Roni

      4 - CHIASMA, INC (0001339469) (Issuer)

      8/5/21 6:00:07 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care

    $CHMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chiasma downgraded by Jefferies

      Jefferies downgraded Chiasma from Buy to Hold

      5/6/21 8:05:49 AM ET
      $CHMA
      Major Pharmaceuticals
      Health Care
    • HC Wainwright resumed coverage on Chiasma with a new price target

      HC Wainwright resumed coverage of Chiasma with a rating of Buy and set a new price target of $12.00 from $10.00 previously

      3/2/21 7:26:29 AM ET
      $CHMA
      Major Pharmaceuticals
      Health Care

    $CHMA
    SEC Filings

    See more
    • SEC Form EFFECT filed by Chiasma, Inc.

      EFFECT - CHIASMA, INC (0001339469) (Filer)

      8/12/21 12:15:07 AM ET
      $CHMA
      Major Pharmaceuticals
      Health Care
    • SEC Form 15-12B filed by Chiasma, Inc.

      15-12B - CHIASMA, INC (0001339469) (Filer)

      8/11/21 4:31:58 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by Chiasma, Inc.

      S-8 POS - CHIASMA, INC (0001339469) (Filer)

      8/6/21 3:17:41 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care

    $CHMA
    Leadership Updates

    Live Leadership Updates

    See more

    $CHMA
    Financials

    Live finance-specific insights

    See more

    $CHMA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer

      Novel Vaccine Company Expands Leadership Team and Establishes US Presence SpyBiotech, a British biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Mark Leuchtenberger as its Chief Executive Officer (CEO). He also joins the Board of Directors. Sumi Biswas, the company's co-founder, remains President and a Director and becomes Chief Scientific Officer (CSO). With the addition of Leuchtenberger, SpyBiotech establishes its presence in the United States with an office in Cambridge, Massachusetts. Mark Leuchtenberger recently served as Executive Chairman for Aleta Biotherapeutics and previously as CEO o

      7/12/22 5:00:00 AM ET
      $CHMA
      $NRSN
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Pulmatrix appoints Director Anand Varadan

      LEXINGTON, Mass., July 27, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced the appointment of Anand Varadan to its Board of Directors, effective July 26, 2021. Mr. Varadan brings expertise in commercialization and successful product launches. In addition, Mark Iwicki stepped down from his role on the Board of Directors effective July 23, 2021. "We are delighted to welcome Anand to

      7/27/21 10:00:00 AM ET
      $PULM
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Chiasma Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update

      Phased launch of MYCAPSSA® progressing with 2020 net product revenue of $1.1 million Achieved payor coverage of MYCAPSSA for over 150 million lives Company to host conference call today, March 4, 2021 at 5:00pm ET NEEDHAM, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to reduce the burden of chronic injections for people with rare diseases, as evidenced by its recent initiation of a phased U.S. commercial launch of MYCAPSSA® as the first oral therapy for treatment of acromegaly, today announced financial results for the fourth quar

      3/4/21 4:01:00 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care
    • Amryt Reports Q3 2022 Financial and Operational Results

      Amryt Reports Q3 2022 Financial and Operational Results 8.2% YoY revenue growth in Q3 to $61.1M - 12.5% on a constant currency basis 11th consecutive quarter of positive EBITDA generation; $12.5M in Q3 2022 Operating cash flows of $14.3M for Q3 2022 Cash of $83.4M at September 30, 2022 Mycapssa® revenues increased 26.9% QoQ to $5.7M and 292.8% YoY CHMP positive opinion for Mycapssa® for the treatment of acromegaly in the EU Pathway agreed with the FDA to initiate a Phase 3 study for NET - expected in Q1 2023 Filsuvez® European launch progressing well Significant metreleptin LATAM $8.3M tender won - revenue expected to be recognized in Q4 Reaffirming FY 2022 revenue guidance to $26

      11/3/22 7:00:00 AM ET
      $AMYT
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Amryt Reports Record Q2 2022 Results

      Amryt Reports Record Q2 2022 Results 9.2% YoY revenue growth in Q2 to $68.5M 35.3% YoY revenue growth in Q2 excluding impact of a sporadic LATAM order in Q2 2021 7.8% growth in metreleptin revenues YoY to $46.4M in Q2 49.9% growth in metreleptin revenues in Q2 excluding impact of a sporadic LATAM order in Q2 2021 10th consecutive quarter of positive EBITDA generation Cash of $90.7M at June 30, 2022 Filsuvez® approved in the EU for the treatment of dystrophic and junctional EB Amryt now has four growing commercial products treating rare diseases Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth Stock repurchase program underway

      8/4/22 7:00:00 AM ET
      $AMYT
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Amryt Reports Record Q1 2022 Results

      Amryt Reports Record Q1 2022 Results CHMP adopts positive opinion for Filsuvez® for the treatment of Dystrophic and Junctional EB Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth Board approved stock repurchase program of up to $30M Cash of $102.2M at March 31, 2022 22.1% YoY revenue growth in Q1 to $59.1M 25.7% growth in metreleptin revenues YoY to $37.6M in Q1 9th consecutive quarter of positive EBITDA generation Successful bioavailability study supporting development of Mycapssa® for carcinoid symptoms in NET Conference call and webcast today at 0830 ET / 1330 BST DUBLIN, Ireland, and Boston MA, May 4, 2022, Amryt (NASDAQ:AMYT), a global, c

      5/4/22 7:00:00 AM ET
      $AMYT
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Amryt Reports Q3 2022 Financial and Operational Results

      Amryt Reports Q3 2022 Financial and Operational Results 8.2% YoY revenue growth in Q3 to $61.1M - 12.5% on a constant currency basis 11th consecutive quarter of positive EBITDA generation; $12.5M in Q3 2022 Operating cash flows of $14.3M for Q3 2022 Cash of $83.4M at September 30, 2022 Mycapssa® revenues increased 26.9% QoQ to $5.7M and 292.8% YoY CHMP positive opinion for Mycapssa® for the treatment of acromegaly in the EU Pathway agreed with the FDA to initiate a Phase 3 study for NET - expected in Q1 2023 Filsuvez® European launch progressing well Significant metreleptin LATAM $8.3M tender won - revenue expected to be recognized in Q4 Reaffirming FY 2022 revenue guidance to $26

      11/3/22 7:00:00 AM ET
      $AMYT
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Amryt Reports Record Q2 2022 Results

      Amryt Reports Record Q2 2022 Results 9.2% YoY revenue growth in Q2 to $68.5M 35.3% YoY revenue growth in Q2 excluding impact of a sporadic LATAM order in Q2 2021 7.8% growth in metreleptin revenues YoY to $46.4M in Q2 49.9% growth in metreleptin revenues in Q2 excluding impact of a sporadic LATAM order in Q2 2021 10th consecutive quarter of positive EBITDA generation Cash of $90.7M at June 30, 2022 Filsuvez® approved in the EU for the treatment of dystrophic and junctional EB Amryt now has four growing commercial products treating rare diseases Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth Stock repurchase program underway

      8/4/22 7:00:00 AM ET
      $AMYT
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer

      Novel Vaccine Company Expands Leadership Team and Establishes US Presence SpyBiotech, a British biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Mark Leuchtenberger as its Chief Executive Officer (CEO). He also joins the Board of Directors. Sumi Biswas, the company's co-founder, remains President and a Director and becomes Chief Scientific Officer (CSO). With the addition of Leuchtenberger, SpyBiotech establishes its presence in the United States with an office in Cambridge, Massachusetts. Mark Leuchtenberger recently served as Executive Chairman for Aleta Biotherapeutics and previously as CEO o

      7/12/22 5:00:00 AM ET
      $CHMA
      $NRSN
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations